{
    "symbol": "SDGR",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-04 20:35:27",
    "content": "  I\u2019d like to remind you that during today\u2019s call, management will make statements related to our business that are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitations, statements related to our future financial performance, including our outlook for the full year 2022 and for the quarter ending June 30, 2022; our strategic plans to accelerate the growth of our software business and advance our collaborative and wholly-owned drug discovery programs; the timing of potential IND submissions and initiation of clinical trials for our wholly-owned drug discovery programs, risks related to the COVID-19 pandemic; our expectations related to the use of our cash, cash equivalents, and marketable securities; as well as our future operating expenses."
}